IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+29.45%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$368M
AUM Growth
+$368M
(+0.58%)
Cap. Flow
-$72.5M
Cap. Flow
% of AUM
-19.73%
Top 10 Holdings %
Top 10 Hldgs %
47.34%
Holding
127
New
24
Increased
22
Reduced
26
Closed
20
Top Buys
| 1 |
Corbus Pharmaceuticals
CRBP
|
$14.3M |
| 2 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$10.9M |
| 3 |
Cytokinetics
CYTK
|
$8.07M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$7.7M |
| 5 |
Pyxis Oncology
PYXS
|
$7.08M |
Top Sells
| 1 |
argenx
ARGX
|
$26.5M |
| 2 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$21.2M |
| 3 |
SPDR S&P Homebuilders ETF
XHB
|
$19.1M |
| 4 |
Nuvalent
NUVL
|
$11.8M |
| 5 |
Disc Medicine
IRON
|
$10.6M |
Sector Composition
| 1 | Healthcare | 98.68% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Crinetics Pharmaceuticals
CRNX
$2.92B
| $30.1M | 3.3% | 643,751 -36,619 | -5% | -$1.71M |
|
2
Tarsus Pharmaceuticals
TARS
$2.47B
| $25.8M | 2.83% | 710,277 +191,758 | +37% | +$6.97M |
|
3
Soleno Therapeutics
SLNO
$3.6B
| $24.2M | 2.65% | 565,411 -24,832 | -4% | -$1.06M |
|
|
4
Corbus Pharmaceuticals
CRBP
$115M
| $21.9M | 2.41% | 559,271 +363,372 | +185% | +$14.3M |
|
5
Sarepta Therapeutics
SRPT
$1.78B
| $19.7M | 2.16% | 152,278 +19,638 | +15% | +$2.54M |
|
|
JBIO
6
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $10.9M | 1.19% | +367,965 | New | +$10.9M |
|
|
SLRN
7
DELISTED
ACELYRIN
SLRN
| $10.6M | 1.16% | 1,564,340 -426,665 | -21% | -$2.88M |
|
|
ALPN
8
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $10.4M | 1.14% | 261,365 -225,883 | -46% | -$8.95M |
|
9
Praxis Precision Medicines
PRAX
$958M
| $10.3M | 1.13% | 168,388 -31,612 | -16% | -$1.93M |
|
|
10
Cytokinetics
CYTK
$4.23B
| $10.2M | 1.12% | 145,147 +115,147 | +384% | +$8.07M |
|
11
Annexon
ANNX
$226M
| $10.1M | 1.1% | 1,405,000 -1,245,000 | -47% | -$8.93M |
|
12
Immunovant
IMVT
$2.56B
| $8.95M | 0.98% | 276,925 +43,531 | +19% | +$1.41M |
|
13
BridgeBio Pharma
BBIO
$9.89B
| $8.72M | 0.96% | 282,013 -191,113 | -40% | -$5.91M |
|
14
Catalyst Pharmaceutical
CPRX
$2.52B
| $8.26M | 0.91% | 518,386 +12,524 | +2% | +$200K |
|
15
Rocket Pharmaceuticals
RCKT
$354M
| $8M | 0.88% | 297,096 +57,370 | +24% | +$1.55M |
|
|
16
Alnylam Pharmaceuticals
ALNY
$58.5B
| $7.7M | 0.84% | +51,541 | New | +$7.7M |
|
|
17
Nuvalent
NUVL
$5.52B
| $7.63M | 0.84% | 101,601 -156,541 | -61% | -$11.8M |
|
|
18
Pyxis Oncology
PYXS
$79.4M
| $7.08M | 0.78% | +1,662,408 | New | +$7.08M |
|
19
Lyra Therapeutics
LYRA
$11.5M
| $6.57M | 0.72% | 1,056,829 -197,555 | -16% | -$1.23M |
|
20
Abeona Therapeutics
ABEO
$350M
| $6.44M | 0.71% | 888,593 +288,593 | +48% | +$2.09M |
|
|
VRNA
21
Verona Pharma
VRNA
$9.16B
| $6.04M | 0.66% | 375,310 +7,842 | +2% | +$126K |
|
22
Arcutis Biotherapeutics
ARQT
$1.86B
| $5.84M | 0.64% | +589,642 | New | +$5.84M |
|
|
CYBN
23
Cybin
CYBN
$176M
| $5.77M | 0.63% | +13,953,488 | New | +$5.77M |
|
24
CervoMed
CRVO
$83.7M
| $5.53M | 0.61% | +237,345 | New | +$5.53M |
|
25
Scholar Rock
SRRK
$3.14B
| $5.18M | 0.57% | +291,701 | New | +$5.18M |
|